Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Benesova A, De Santis S, Polivkova V, Pecherkova P, Krizkova J, Suchankova P, Monaldi C, Klamova H, Srbova D, Zizkova H, Hochhaus A, Soverini S, Machova Polakova K. Benesova A, et al. Among authors: hochhaus a. Am J Hematol. 2024 Apr;99(4):759-762. doi: 10.1002/ajh.27232. Epub 2024 Feb 5. Am J Hematol. 2024. PMID: 38314531 No abstract available.
Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis.
Eisenach S, Zinke J, Brämer D, Hartinger S, Haferlach T, Kreipe HH, Hammersen J, Hamadanchi A, Otto S, Schulze PC, Bürckenmeyer F, Teichgräber U, Hochhaus A, Witte OW, Günther A, Schrenk KG. Eisenach S, et al. Among authors: hochhaus a. Ann Hematol. 2024 Jan;103(1):363-365. doi: 10.1007/s00277-023-05490-1. Epub 2023 Oct 16. Ann Hematol. 2024. PMID: 37843619 Free PMC article. No abstract available.
Mutations in the plasma cell clone identify mechanism of polyneuropathy in a case of POEMS syndrome associated with Castleman disease and multiple myeloma.
Brioli A, Wyrwa A, Rüddel U, Yomade O, Lindig U, Franz W, Wacker HH, Gaßler N, Schweyer S, Chung HY, Axer H, Witte OW, Hochhaus A, Schrenk KG. Brioli A, et al. Among authors: hochhaus a. Ann Hematol. 2023 Jan;102(1):239-242. doi: 10.1007/s00277-022-05032-1. Epub 2022 Nov 19. Ann Hematol. 2023. PMID: 36401620 Free PMC article. No abstract available.
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HK, Schwind S, Jentzsch M, Cross M, Kahl C, Wolf HH, Sayer H, Schulze A, Dreger P, Hegenbart U, Krämer A, Junghanss C, Mügge LO, Hähling D, Hirt C, Späth C, Peter N, Opitz B, Florschütz A, Reifenrath K, Zojer N, Scholl S, Pönisch W, Heyn S, Vucinic V, Hochhaus A, Aul C, Giagounidis A, Balleisen L, Oldenkott B, Staib P, Kiehl M, Schütte W, Naumann R, Eimermacher H, Dörken B, Sauerland C, Lengfelder E, Hiddemann W, Wörmann B, Müller-Tidow C, Serve H, Schliemann C, Hehlmann R, Berdel WE, Pfirrmann M, Krug U, Hoffmann VS. Niederwieser D, et al. Among authors: hochhaus a. Ann Hematol. 2023 Mar;102(3):547-561. doi: 10.1007/s00277-023-05087-8. Epub 2023 Jan 25. Ann Hematol. 2023. PMID: 36695874 Free PMC article.
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A, Saussele S, Kiani A, Göthert JR, Illmer T, Schafhausen P, Al-Ali HK, Stegelmann F, Hänel M, Pfeiffer T, Giagounidis A, Franke GN, Koschmieder S, Fabarius A, Ernst T, Warnken-Uhlich M, Wolber U, Kohn D, Pfirrmann M, Wolf D, Brümmendorf TH; German CML study group. Isfort S, et al. Among authors: hochhaus a. Ann Hematol. 2023 Oct;102(10):2741-2752. doi: 10.1007/s00277-023-05394-0. Epub 2023 Aug 18. Ann Hematol. 2023. PMID: 37592092 Free PMC article. Clinical Trial.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Koschmieder S, et al. Among authors: hochhaus a. Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. Ann Hematol. 2023. PMID: 36564535 Free PMC article. Clinical Trial.
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.
Eckardt JN, Stasik S, Röllig C, Petzold A, Sauer T, Scholl S, Hochhaus A, Crysandt M, Brümmendorf TH, Naumann R, Steffen B, Kunzmann V, Einsele H, Schaich M, Burchert A, Neubauer A, Schäfer-Eckart K, Schliemann C, Krause SW, Herbst R, Hänel M, Hanoun M, Kaiser U, Kaufmann M, Rácil Z, Mayer J, Oelschlägel U, Berdel WE, Ehninger G, Serve H, Müller-Tidow C, Platzbecker U, Baldus CD, Dahl A, Schetelig J, Bornhäuser M, Middeke JM, Thiede C. Eckardt JN, et al. Among authors: hochhaus a. Leukemia. 2023 Dec;37(12):2395-2403. doi: 10.1038/s41375-023-02061-1. Epub 2023 Oct 13. Leukemia. 2023. PMID: 37833543 Free PMC article.
[Vorwort des DGHO-Vorstands].
Einsele H, Hochhaus A, de Wit M, Schulz CO. Einsele H, et al. Among authors: hochhaus a. Oncol Res Treat. 2023;46 Suppl 4:1. doi: 10.1159/000533464. Epub 2023 Sep 25. Oncol Res Treat. 2023. PMID: 37748445 Free article. German. No abstract available.
704 results